For adults over 70 who never had a heart attack or stroke, a trial asked what happens if they stop statins. A randomized study of 1,880 older adults found this. The two-year risk of a heart event or death did not rise by much. Many also help a parent manage daily medications. The tradeoff, though, is not as clean as that two-year result suggests.
Statins are prescription medications that lower LDL, or “bad,” cholesterol. Researchers estimate that about 25% of U.S. adults have high LDL cholesterol. Too much LDL can build up in the arteries. This can slow blood flow and lead to heart attacks and strokes. Many people have been on statins for years, sometimes decades. This research examined exactly that use.
What the STREAM Trial Actually Tested
The open-label, randomized trial is called STREAM. Researchers enrolled 1,880 adults at 24 sites in Switzerland, the Netherlands, and France. The study ran from November 2021 through April 2026. Every participant was aged 70 or older and taking statins for primary prevention. Each also had at least two chronic conditions, such as past cancer or pulmonary disease. People who already had heart disease or a history of heart attack or stroke were not eligible.
Researchers randomly assigned people in a 1:1 ratio to stop or continue statin therapy. They tracked health over a median follow-up of about two years. Researchers followed some people for up to four years. The main outcome was time free of a first nonfatal heart attack, a nonfatal ischemic stroke, or death from any cause.
What the Two-Year Data Showed
At two years, stopping statins was noninferior to continuing them. The difference in event-free survival time between groups was minus 2.0 weeks. That fell inside the pre-set non-inferiority margin of minus 5.2 weeks. People who stopped their statin lost about two weeks of event-free time. That was compared with those who kept taking it. That gap was small enough that the trial called stopping statins “non-inferior” by its pre-set standard.
Read More: Common Heart Pill Under Scrutiny for Older Patients as Study Weighs Risks of Stopping
Non-inferiority is a specific trial standard. It means the treatment tested did not fall below an agreed-upon limit for an acceptable difference. It does not mean there was no difference at all. The median follow-up was 103 weeks. During that time, 119 people (12.7%) in the stopping group had a primary outcome event. In the group that kept taking the statin, 87 people (9.2%) had a primary outcome event. The share was higher in the group that stopped. Those rates reflect raw numbers and are not adjusted for other factors. A difference between the two groups was still present.
Quality of life, muscle discomfort, falls, and muscle wasting were similar in both groups at two years.
Stopping Statins After 70: What the Longer Follow-Up Showed
Extended follow-up of up to four years showed a small but meaningful increase in risk. That increase was seen among those who stopped. Dr. Rita F. Redberg is a professor of cardiology at the University of California, San Francisco School of Medicine. She also holds the Araxe Vilensky Endowed Chair in Cardiology there. She said this finding was new in the scientific literature. She said it may be because this trial had more people and a longer follow-up than past studies.
Redberg said: “This small, increased risk of heart events means that one cannot make a general recommendation about stopping statins in this patient population.” She also said: “In general, however, stopping is safe for most people who are in this age group and without a previous CVD event.”
The trial’s own calculation puts a clearer number on the tradeoff. For about every 40 people who stopped their statin, one extra major heart event or death occurred over two years. That was compared to those who kept taking it. For some people, in some cases, stopping may be a fair choice. For others, it may not.
Earlier studies found no difference in death rates after adults 70 and older stopped statins for primary prevention. One study suggested quality of life improvements after stopping. Redberg said the STREAM trial was larger and ran longer than past studies. That may be why it did not show the same quality-of-life benefit.
This Finding Does Not Apply to Everyone
The STREAM findings apply only to adults 70 and older. They apply to people who were taking statins for primary prevention. That means they had no prior heart attack, stroke, or known heart disease. This is a specific and important distinction. If you or a parent already has heart disease, or has had a stroke, the case for staying on a statin is much stronger. The STREAM results do not speak to that group at all.
Some in the stopping group restarted their statin. Some in the continuation group stopped. The researchers ran additional analysis to account for this crossover. That analysis did not change the main results.
The trial was open-label. That means people and their doctors knew which group they were in. That may have influenced behavior. About 14% of people did not follow their assigned plan. That design can introduce bias. To reduce that risk, the trial used blinded outcome adjudication. The team that judged whether an event actually occurred did not know which group a person was in.
Talking to Your Doctor About Stopping Statins
The STREAM trial was presented at the American Heart Association Scientific Sessions 2026 on November 7, 2026. It was published the same day in the New England Journal of Medicine. Stopping statins for primary prevention was generally safe at two years. That was among older adults with no history of heart disease. In the extended follow-up of up to four years, serious events occurred more often in those who stopped. Serious events occurred in 12.7% of the stopping group and 9.2% of the continuation group. That gap means the decision deserves more than a quick conversation with your doctor.
Statins are not a medication to stop without guidance. If you are 70 or older and took a statin only to prevent a first heart event, talk with your doctor. The STREAM data gives you something to discuss. This is especially true if you have other long-term health conditions. It is also true if you are thinking about whether to keep taking a statin.
Some women in their 50s and 60s are already taking a statin to prevent heart disease. Knowing what the evidence shows at age 70 and beyond can help. You can use that knowledge to make a plan with your doctor before the question comes up. Bring the question to your next appointment. Ask specifically whether you are on a statin for primary or secondary prevention. That one difference will decide how much this research applies to your situation.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.